GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Antihyperglycemic therapy

Company
Takeda
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
2 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

2 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for Antihyperglycemic therapy and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT05933161

    A Study of Glycemic Control in Left Ventricular Assist

    Mayo Clinic 20 participants Est. completion 2027-07 1 site
    Type 2 diabetes Other conditions: Hyperglycemia, Hypoglycemia
    View official trial listing →
  • Recruiting NCT NCT07258394

    Clinical Study for Dimethyl Fumarate in Preserving Islet β-Cell Function in Type 1 Diabetes Mellitus

    Not yet reported Nanjing Medical University 90 participants Est. completion 2028-12-31 1 site
    Other conditions: Type 1 Diabetes
    View official trial listing →
  • Completed NCT NCT00357370

    A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes

    Not yet reported, Not yet reported AstraZeneca 163 participants Est. completion 2008-03 23 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00481663

    A Study of Different Doses of Sitagliptin (MK-0431) in Participants With Type 2 Diabetes Mellitus (MK-0431-014)

    Not yet reported Merck Sharp & Dohme LLC 555 participants Est. completion 2006-05-14 Stand-alone
    Other conditions: Type II Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT01871428

    A Study of Aleglitazar in Monotherapy in Patients With Type 2 Diabetes Mellitus Who Are Drug-Naïve to Anti-Hyperglycemic Therapy

    Not yet reported Hoffmann-La Roche 13 participants Est. completion 2013-11 7 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01986855

    A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001)

    Not yet reported Merck Sharp & Dohme LLC 468 participants Est. completion 2016-09-28
    Type 2 diabetes
    View official trial listing →
  • Withdrawn NCT NCT02015780

    Fasiglifam in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or 5 on Hemodialysis

    Not yet reported Takeda Est. completion 2016-01 30 sites Stand-alone
    Type 2 diabetesChronic kidney disease
    View official trial listing →
  • Completed NCT NCT02320721

    Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications

    Not yet reported Sanofi 1014 participants Est. completion 2016-05 162 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02855684

    Comparison of the Efficacy and Safety of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Insufficiently Controlled With Non-insulin Antidiabetic Therapy

    Not yet reported Sanofi 604 participants Est. completion 2018-08-06 54 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT04562714

    Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy

    Not yet reported LMC Diabetes & Endocrinology Ltd. 116 participants Est. completion 2022-09-06 6 sites
    Type 2 diabetes Other conditions: Glucose
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.